// App-Quantinova.ai

393 : Reference values for EORTC QLQ-C30, for metastatic pancreatic cancer (mPC): Enhancing the interpretation of HRQoL scores in the POLO trial.

Researchers

Presenter

  • Hedy L. Kindler

Principal Investigators

  • Suvina Amin

  • Seongjung Joo

  • Nikunj Patel

  • Hyun Kyoo Yoo

  • Colin Johnson

  • Hilary Byrnes

  • Sara Costa-Cabral

  • Sandra Nolte

Medical Centers

  • The University of Chicago Medical Center, Chicago, IL

  • AstraZeneca, Gaithersburg, MD

  • Merck & Co., Inc., Kenilworth, NJ

  • Southampton University Hospitals NHS Trust, Southhampton, United Kingdom

  • COTA, New York, NY

  • Mapi Research Trust,Lyon,France

  • ASCA GmbH, Berlin, Germany.

Locations

  • United States

  • United Kingdom

  • France

  • Germany

Companies

  • Merck & Co., Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Metastatic pancreatic adenocarcinoma

Biomarkers

  • N/A

Drug/Treatment

  • Olaparib

Outcome

  • N/A

Study Design

  • Placebo Control

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved